The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0

Journal of Nuclear Medicine

Volumn 53, Issue 10, 2012, Pages 1633-1651

  Silberstein, Edward B ^a   Alavi, Abass ^b   Balon, Helena R ^c   Clarke, Susan E M ^d   Divgi, Chaitanya ^e   Gelfand, Michael J ^f   Goldsmith, Stanley J ^g   Jadvar, Hossein ^h   Marcus, Carol S ⁱ   Martin, William H ^j   Parker, J Anthony ^k   Royal, Henry D ^l   Sarkar, Salil D ^m   Stabin, Michael ⁿ   Waxman, Alan D ^o  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d GUY S HOSPITAL   (United Kingdom)

^e Department of Medicine   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g WEILL CORNELL MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m JACOBI MEDICAL CENTER   (United States)

ⁿ VANDERBILT UNIVERSITY   (United States)

^o CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN;

BLOOD EXAMINATION; BONE PAIN; CANCER STAGING; DENTAL CARIES; DOSE RESPONSE; DOSIMETRY; DRUG DOSE COMPARISON; DYSGEUSIA; DYSPNEA; EPIPHORA; FOLLOW UP; GRAVES DISEASE; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HUMAN; HYPOTHYROIDISM; INFECTION CONTROL; INFERTILITY; INFORMED CONSENT; LACTATION; LEUKOCYTE COUNT; MEDICAL DOCUMENTATION; NAUSEA; NECK PAIN; NODULAR GOITER; ORAL MUCOSITIS; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RADIATION SAFETY; REVIEW; SIALOADENITIS; SIALOLITHIASIS; SIDE EFFECT; TASTE DISORDER; THROMBOCYTE COUNT; THYROID CANCER; THYROID DISEASE; THYROID SCINTISCANNING; TOXIC GOITER; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR ABLATION; VOMITING; XEROPHTHALMIA; XEROSTOMIA;

CHILD; DOCUMENTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MOLECULAR IMAGING; NUCLEAR MEDICINE; PREGNANCY; QUALITY CONTROL; RADIOTHERAPY; RESEARCH REPORT; SAFETY; SOCIETIES, SCIENTIFIC; THYROID DISEASES;

EID: 84867036640     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105148     Document Type: Review

References (121)

1. Stopping Power for Electrons and Positrons. Bethesda, MD: ICRU; 1984:206. Report 37.
2. Eckerman KF, Endo A. MIRD: Radionuclide Data and Decay Schemes. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; 2008.
3. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235-1245.
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
5. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed., New York, NY: Springer; 2009:87-96.
6. Mazzaferri EL. Managing small thyroid cancers. JAMA. 2006;295:2179-2182.
7. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid cancer: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery.1993;114:1050-1058. (Pubitemid 24004722)
8. Hermus AR, Huysmans DAKC. Treatment of benign nodular thyroid disease. N Engl J Med. 1998;338:1438-1447.
9. Huysmans DAKC, Hermus ARMM, Corstens FH, Berentsz JC, Kloppenborg PW. Large compressive goiters treated with radioiodine. Ann Intern Med. 1994;121:757-762.
10. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine-131 treatment as an alternative to surgery in patients with a very large goiter: effect of thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636-3641. (Pubitemid 30645217)
11. Conjoint statement of the SNM, ACNM, and ABNM on credentialing and delineation of privileges for therapeutic procedures using radiopharmaceuticals. J Nucl Med. 2011;52:323-326.
12. ACGME Program Requirements for Graduate Medical Education in Nuclear Medicine. Chicago, IL: ACGME; July 1, 2011.
13. Werner MC, Romaldini JH, Bomberg N, et al. Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci. 1989;297:216-219. (Pubitemid 19104028)
14. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioiodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86:3488-3493. (Pubitemid 32755934)
15. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87:1073-1077.
16. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment of Graves' hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12:135-139. (Pubitemid 34213997)
17. Release of individuals containing unsealed byproduct material or implants containing byproduct material. Title 10 of Code of Federal Regulations part 35.75.
18. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid. 2010;20:785-793.
19. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347-355. (Pubitemid 28503219)
20. Graham GD, Burman KD. Radioiodine treatment of Graves' disease: an assessment of its potential risks. Ann Intern Med. 1986;105:900-905. (Pubitemid 17201771)
21. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14:832-839.
22. 131I activity to be administered in patients with low uptake. Thyroid. 2011;21:759-764.
23. 99mTc pertechnetate thyroid uptake ratio and neck/thigh ratio. AJR. 1979;132:249-253.
24. 99mTc-pertechnetate uptake for routine assessment of thyroid structure and function. J Clin Endocrinol Metab. 1973;36:317-322.
25. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Endocrinologists. Endocr Pract. 2011;17:456-520.
26. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med. 1994;331:1072-1078.
27. Tran P, Desimone S, Barrett M, Bachrach B. I-131 treatment of Graves' disease in an unsuspected first trimester pregnancy: the potential for adverse effects on the fetus and a review of the current guidelines for pregnancy screening. Int J Pediatr Endocrinol. March 14, 2010 [Epub ahead of print].
28. Brzozowska M, Roach PJ. Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer. Clin Nucl Med. 2006;31:683-687. (Pubitemid 44624553)
29. Stabin MG, Blackwell R, Brent RL, et al. Fetal Radiation Dose Calculations. Washington, DC: American National Standards Institute; 2008. ANSI N13.54-2008.
30. Stabin MG, Breitz H. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-873. (Pubitemid 30266032)
31. Hsiao E, Huynh T, Mansberg R, Bautovich R, Roach P. Diagnostic I-123 scintigraphy to assess potential breast uptake of I-131 before radioiodine therapy in a postpartum woman with thyroid cancer. Clin Nucl Med. 2004;29:498-501. (Pubitemid 38970698)
32. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321-1331. (Pubitemid 43132677)
33. Leslie WD, Ward L, Salamon EA, et al. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978-983. (Pubitemid 36337742)
34. Reinhardt MJ, Brink I, Joe AY, et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pretreatment thyroid volume on the final outcome. Eur J Nucl Med Mol Imaging. 2002;29:1118-1124. (Pubitemid 34985354)
35. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer. 2010;17:R161-R172.
36. Kobe C, Eschner W, Sudbrock F, et al. Graves' disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2007;47:13-17. (Pubitemid 351272805)
37. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioidine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf). 2005;62:331-335. (Pubitemid 40380414)
38. Ratcliffe GE, Coke S, Fogelman I, Maisey MN. Radioiodine treatment of solitary functioning nodules. Br J Radiol. 1986;59:385-387. (Pubitemid 16092866)
39. Tzvetov G, Hirsch D, Shrago-Slutzky IS, et al. Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. Thyroid. 2009;19:487-494.
40. Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey TJ Jr. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid. 2009;19:473-477.
41. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implications of papillary thyroid microcarcinoma. Thyroid. 2007;17:1085-1092. (Pubitemid 350207746)
42. So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148:526-531.
43. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242. (Pubitemid 46080167)
44. Blum M, Tiu S, Chu M, et al. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post thyroidectomy thyroid cancer patients. Thyroid. 2011;21:1235-1247.
45. Van Nostrand D, Aiken M, Atkins F, et al. The utility of radioiodine scans prior to iodine-131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:849-855.
46. Wong KK, Zarzhevsky N, Cahill JM, et al. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009;82:860-876.
47. 131I SPECT-CT. AJR. 2010;195:730-736.
48. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med. 1986;27:637-640.
49. Goffman T, Ioffe V, Tuttle M. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid cancer. Thyroid. 2003;13:827-830. (Pubitemid 37070164)
50. 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007;48:1043-1046.
51. 123I. Eur J Nucl Med Mol Imaging. 2002;29:783-788.
52. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in I-131-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507-3511. (Pubitemid 32755936)
53. Alam MS, Takeuchi R, Kasagi K, et al. Value of combined technetium-99m hydroxyl methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma. Thyroid. 1997;7:705-712. (Pubitemid 28086201)
54. Ito S, Kato K, Ikeda M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889-895. (Pubitemid 46909916)
55. Schirrmeister H, Buck A, Guhlman A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid. 2001;11:677-683. (Pubitemid 32701589)
56. 131I whole body scans and elevated thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.
57. Robbins RJ, Larson SM. The value of positron emission tomography (PET) in the management of patients with thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:1047-1059.
58. Abraham T, Schoder H. Thyroid cancer: indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med. 2011;41:121-138.
59. 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37:2267-2276.
60. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58:428-435. (Pubitemid 36390614)
61. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med. 2004;45:567-570. (Pubitemid 47618586)
62. Radioactive iodine (RAI). ThyCa: Thyroid Cancer Survivors Association Web site. Available at: http://www.thyca.org/rai.htm. Accessed February 8, 2012.
63. Matovic MD, Jankovic SM, Jeremic M, Tasic Z, Vlakjovic M. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine-131. Thyroid. 2009;19:843-848.
64. Pacini F, Schlumberger M, Dralle H, Elisei R, Smot JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
65. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid stimulating hormone. J Endocrinol Invest. 2002;25:44-52. (Pubitemid 34168339)
66. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482-1488. (Pubitemid 35285874)
67. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764-770. (Pubitemid 351717542)
68. Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TShH. J Clin Endocrinol Metab. 2011;96:2105-2111.
69. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265-271. (Pubitemid 36459308)
70. Ma C, Xie J, Jiang Z, et al. Does amifostine have radioprotective effects on the salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer? Eur J Nucl Med Mol Imaging. 2010;37:1778-1785.
71. 131I-induced- sialadenitis: the role of pilocarpine. J Nucl Med. 2008;49:546-549.
72. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46:261-266. (Pubitemid 43073433)
73. Drouet M, Herodin F. Radiation victim management and the hematologist in the future: time to revisit therapeutic guidelines? Int J Radiat Biol. 2010;86:636-648.
74. Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. 1962;87:171-182.
75. Rosário PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid. 2006;16:667-670.
76. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L. Differentiated thyroid carcinoma in children and adolescents: a 37 year experience in 85 patients. J Nucl Med. 1997;38:669-675. (Pubitemid 27204036)
77. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf). 2002;56:755-758. (Pubitemid 34785906)
78. Esfahani AF, Eftekhari M, Zenooz N, Saghari M. Gonadal function in patients with differentiated thyroid cancer treated with 131I. Hell J Nucl Med. 2004;7:52-55. (Pubitemid 38679031)
79. Smith MB, Xue H, Takahashi H, Cangir A, Andrassy RJ. Iodine 131 thyroid ablation in female children and adolescents; long-term risk of infertility and birth defects. Ann Surg Oncol. 1994;1:128-131.
80. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med. 1995;36:21-27.
81. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 2. Chapter 12. Washington, DC: The National Academies Press; 2006.
82. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-515. (Pubitemid 351240823)
83. Sandeep TC, Strachan MWJ, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91:1819-1825.
84. U.S. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Database, 2005-2007.
85. Pitoia F, Ilera V, Zanchetta MB. Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end stage renal disease. Endocr Pract. 2008;14:961-966.
86. van der Molen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Contrast Media Safety Committee, European Society of Urogenital Radiology. Eur Radiol. 2004;14:902-907.
87. Johansen K, Woodhouse NJY, Odugbesan O. Comparison of 1073 MBq and 3700 MBq in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med. 1991;32:252-254.
88. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542-3546. (Pubitemid 47435333)
89. Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol. 2003;12:91-99. (Pubitemid 37289014)
90. Lassmann M, Hanscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard procedures for pre-therapeutic dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405-1412.
91. Thomas SR, Samaratunga RC, Sperling M, et al. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol. 1993;20:157-162. (Pubitemid 23043069)
92. Kulkarni K, van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16:1019-1023. (Pubitemid 46141304)
93. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587-1591. (Pubitemid 47545022)
94. Sgouros G, Song H, Ladenson PW, et al. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006;47:1977-1984. (Pubitemid 47544985)
95. Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41:113-120.
96. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullen BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521-1526. (Pubitemid 34615232)
97. 13I I ablative therapy. J Nucl Med. 1999;40:1434-1440.
98. Pons F, Carrio I, Estorch M, Ginjuame M, Pons J, Milian R. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med. 1987;12:644-647. (Pubitemid 17150081)
99. 131I therapy of metastatic well differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:912-916.
100. 131I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94:2075-2084.
101. 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952-1957.
102. 131I SPECT-CT offers high diagnostic accuracy when the findings on the conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36:886-893.
103. 131I-SPECT/CT at first radioablation. Eur J Nucl Med Mol Imaging. 2010;37:699-705.
104. 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18-23.
105. Siegel JA, Marcus CS, Stabin MG. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I. Health Phys. 2007;93:667-677. (Pubitemid 350098504)
106. RADAR medical procedure radiation dose calculator and consent language generator. RADAR - the RAdiation Dose Assessment Resource Web site. Available at: http://www.doseinfo-radar.com/RADARDoseRiskCalc.html. Accessed February 8, 2012.
107. Siegel J. Guide for Diagnostic Nuclear Medicine and Radiopharmaceutical Therapy. Reston, VA: Society of Nuclear Medicine; 2004.
108. Consolidated guidance about materials licenses: program-specific guidance about medical use licenses (NUREG-1556, volume 9, revision 2, appendix U, table U.1). United States Nuclear Regulatory CommissionWeb site. Available at: http://www. nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/ sr1556v9r2-final-appendices-i-w.pdf. Published January 2008. Accessed February 8, 2012.
109. St. Germain J, Silberstein EB, Vetter RJ, et al. NCRP Report No. 155: Management of Radionuclide Therapy Patients. Bethesda, MD: National Council on Radiation Protection and Measurements; 2006.
110. Zanzonico PB. Radiation dose to patients and relatives incident to 131I therapy. Thyroid. 1997;7:199-204. (Pubitemid 27190580)
111. Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (I-131) therapy for thyroid carcinoma. JAMA. 2000;283:2272-2274. (Pubitemid 30246779)
112. NRC Policy on Release of Iodine-131 Therapy Patients Under 10 CFR 35.75 to Locations Other Than Private Residences. Rockville, MD: Nuclear Regulatory Commission; January 25, 2011.
113. 131I for differentiated thyroid cancer: radiation dose to the ovaries and outcome of pregnancies. J Nucl Med. 2008;49:845-852.
114. Hobbs RF, McNutt T, Baechler S, et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys. 2011;80:1256-1262.
115. Compliance Policy Guides, section 460.200, Pharmacy Compounding. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/ICECI/ ComplianceManuals/CompliancePolicyGuidanceManual/ucm074398.htm. PublishedMarch 16, 1992. ReissuedMay 29, 2002. Accessed February 9, 2012.
116. Flux GD, Haq M, Chittenden SJ, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:270-275.
117. 131I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879-883.
118. 124I PET: comparison of PET/MRI vs. PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011;38:1862-1868.
119. ICRP publication 53: radiation dose to patients from radiopharmaceuticals. Ann ICRP. 1988;18:275-278.
120. Russell JR, Stabin MG, Sparks RB, Watson EE. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. Health Phys. 1997;73:756-769. (Pubitemid 27444395)
121. Watson EE. Radiation absorbed dose to the human fetal thyroid. In: Fifth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, Tennessee: Oak Ridge Associated Universities; 1992:179-187.